INM SEC-Einreichungen - InMed Pharmaceuticals Inc.- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

LEI	549300VA5DNHEJGHG397
CIK	1728328

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to InMed Pharmaceuticals Inc.

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

May 19, 2026	EX-99.3	[END OF TRANSCRIPT] Exhibit 99.3 InMed Pharmaceuticals Investor Webcast Script: Scheduled for 5.19.26, 8:30AM ET Format: Pre-recorded, audio only, 15-20minutes, no slides or Q&A Corporate Participants: ● Colin Clancy - VP, Investor Relations and Corporate Communications, InMed Pharmaceuticals ● Eric A. Adams – President & Chief Executive Officer, InMed Pharmaceuticals ● Julianne Bruno - Chair of the Board, Mentari Th
May 19, 2026	EX-99.2	M AY 2 0 2 6 Mentari Therapeutics Overview 2 Disclaimers The information contained in this presentation has been prepared by Mentari Therapeutics, Inc. and its affiliates ("we," "us," "our" or the "Company") and contains information pertaining to the Exhibit 99.2 M AY 2 0 2 6 Mentari Therapeutics Overview 2 Disclaimers The information contained in this presentation has been prepared by Mentari Therapeutics, Inc. and its affiliates ("we," "us," "our" or the "Company") and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subjec
May 19, 2026	EX-10.1	FORM OF PARENT SUPPORT AGREEMENT Exhibit 10.1 FORM OF PARENT SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of May 19, 2026, by and among Mentari Therapeutics, Inc., a Delaware corporation (the “Company”), InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (“Parent”), and the undersigned shareholder of Parent (the “Shareholder” and each of
May 19, 2026	EX-2.1	AGREEMENT AND PLAN OF MERGER AND REORGANIZATION Mentari Therapeutics, Inc.; INDIGO MERGER SUB CORP.; INDIGO MERGER SUB II, LLC; and InMed Pharmaceuticals Inc. Dated as of May 19, 2026 TABLE OF CONTENTS Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: Mentari Therapeutics, Inc.; INDIGO MERGER SUB CORP.; INDIGO MERGER SUB II, LLC; and InMed Pharmaceuticals Inc. Dated as of May 19, 2026 TABLE OF CONTENTS Page Section 1. Definitions and Interpretative Provisions 3 1.1 Definitions 3 1.2 Other Definitional and Interpretative Provisions 19 Section 2. Description of Transaction 20 2.1
May 19, 2026	EX-2.1	AGREEMENT AND PLAN OF MERGER AND REORGANIZATION Mentari Therapeutics, Inc.; INDIGO MERGER SUB CORP.; INDIGO MERGER SUB II, LLC; and InMed Pharmaceuticals Inc. Dated as of May 19, 2026 TABLE OF CONTENTS Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: Mentari Therapeutics, Inc.; INDIGO MERGER SUB CORP.; INDIGO MERGER SUB II, LLC; and InMed Pharmaceuticals Inc. Dated as of May 19, 2026 TABLE OF CONTENTS Page Section 1. Definitions and Interpretative Provisions 3 1.1 Definitions 3 1.2 Other Definitional and Interpretative Provisions 19 Section 2. Description of Transaction 20 2.1
May 19, 2026	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2026 INMED PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2026 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-39685 98-1428279 (State or other jurisdiction of incorporat
May 19, 2026	EX-99.1	InMed Pharmaceuticals Amends Preferred Investment Options NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Amends Preferred Investment Options Vancouver, BC - May 19, 2026 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candid
May 19, 2026	EX-10.4	CONTINGENT VALUE RIGHTS AGREEMENT Exhibit 10.4 CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of May 19, 2026, is entered into by and between InMed Pharmaceuticals, Inc., a corporation organized under the laws of British Columbia, Canada (the “Parent”), and [], a [], as the “Rights Agent” (as defined herein), and [], a [], solely in its capacity as the initial representative,
May 19, 2026	EX-99.1	InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies Mentari’s parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal Exhibit 99.1 NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies Mentari’s parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a subo
May 19, 2026	EX-99.3	[END OF TRANSCRIPT] Exhibit 99.3 InMed Pharmaceuticals Investor Webcast Script: Scheduled for 5.19.26, 8:30AM ET Format: Pre-recorded, audio only, 15-20minutes, no slides or Q&A Corporate Participants: ● Colin Clancy - VP, Investor Relations and Corporate Communications, InMed Pharmaceuticals ● Eric A. Adams – President & Chief Executive Officer, InMed Pharmaceuticals ● Julianne Bruno - Chair of the Board, Mentari Th
May 19, 2026	EX-10.2	FORM OF COMPANY SUPPORT AGREEMENT Exhibit 10.2 FORM OF COMPANY SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of May 19, 2026, by and among Mentari Therapeutics, Inc., a Delaware corporation (the “Company”), InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (“Parent”), and the undersigned stockholder of the Company (the “Stockholder” and e
May 19, 2026	EX-10.1	PREFERRED INVESTMENT OPTION INMED PHARMACEUTICALS INC. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.
May 19, 2026	EX-10.2	FORM OF COMPANY SUPPORT AGREEMENT Exhibit 10.2 FORM OF COMPANY SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of May 19, 2026, by and among Mentari Therapeutics, Inc., a Delaware corporation (the “Company”), InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (“Parent”), and the undersigned stockholder of the Company (the “Stockholder” and e
May 19, 2026	EX-10.5	SECURITIES PURCHASE AGREEMENT Exhibit 10.5 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May 19, 2026, by and among Mentari Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the Persons listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering t
May 19, 2026	EX-10.1	FORM OF PARENT SUPPORT AGREEMENT Exhibit 10.1 FORM OF PARENT SUPPORT AGREEMENT This Support Agreement (this “Agreement”) is made and entered into as of May 19, 2026, by and among Mentari Therapeutics, Inc., a Delaware corporation (the “Company”), InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (“Parent”), and the undersigned shareholder of Parent (the “Shareholder” and each of
May 19, 2026	EX-10.3	FORM OF LOCK-UP AGREEMENT Exhibit 10.3 FORM OF LOCK-UP AGREEMENT [], 2026 InMed Pharmaceuticals Inc. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 Attention: [] Email: [] Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (in
May 19, 2026	EX-99.2	M AY 2 0 2 6 Mentari Therapeutics Overview 2 Disclaimers The information contained in this presentation has been prepared by Mentari Therapeutics, Inc. and its affiliates ("we," "us," "our" or the "Company") and contains information pertaining to the Exhibit 99.2 M AY 2 0 2 6 Mentari Therapeutics Overview 2 Disclaimers The information contained in this presentation has been prepared by Mentari Therapeutics, Inc. and its affiliates ("we," "us," "our" or the "Company") and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subjec
May 19, 2026	EX-10.4	CONTINGENT VALUE RIGHTS AGREEMENT Exhibit 10.4 CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of May 19, 2026, is entered into by and between InMed Pharmaceuticals, Inc., a corporation organized under the laws of British Columbia, Canada (the “Parent”), and [], a [], as the “Rights Agent” (as defined herein), and [], a [], solely in its capacity as the initial representative,
May 19, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2026 INMED PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2026 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-39685 98-1428279 (State or other jurisdiction of incorporat
May 19, 2026	EX-10.5	SECURITIES PURCHASE AGREEMENT Exhibit 10.5 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May 19, 2026, by and among Mentari Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the Persons listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering t
May 19, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39685 98-1428279 (State or other jurisdiction (Commission (IRS Empl
May 19, 2026	EX-99.1	InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies Mentari’s parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal Exhibit 99.1 NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies Mentari’s parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a subo
May 19, 2026	EX-10.3	FORM OF LOCK-UP AGREEMENT Exhibit 10.3 FORM OF LOCK-UP AGREEMENT [], 2026 InMed Pharmaceuticals Inc. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 Attention: [] Email: [] Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (in
May 7, 2026	EX-99.1	InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update Vancouver, BC - May 6th, 2026 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a pharmaceutical company focused on developing a pipeline of propriet
May 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39685 98-1428279 (State or other jurisdiction (Commission (IRS Emplo
May 6, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTICAL
April 27, 2026	EX-10.2	Form OF preferred investment option AMENDING AGREEMENT Exhibit 10.2 Form OF preferred investment option AMENDING AGREEMENT THIS PREFERRED INVESTMENT OPTION AMENDING AGREEMENT (the “Agreement”) is dated April 24, 2026 between: [ ]1 (the “Holder”) -and- INMED PHARMACEUTICALS INC. (the “Company”). WHEREAS: (A) pursuant to the terms of Preferred Investment Options dated November 21, 2022, October 26, 2023, and June 26, 2025 (together, the “Preferred Inves
April 27, 2026	EX-10.1	preferred investment option AMENDING AGREEMENT Exhibit 10.1 preferred investment option AMENDING AGREEMENT THIS PREFERRED INVESTMENT OPTION AMENDING AGREEMENT (the “Agreement”) is dated April 21, 2026 between: SABBY VOLATILITY WARRANT MASTER FUND, LTD. (the “Holder”) -and- INMED PHARMACEUTICALS INC. (the “Company”). WHEREAS: (A) pursuant to the terms of Preferred Investment Options dated October 26, 2023 and June 26, 2025 (together, the “Prefe
April 27, 2026	EX-99.1	InMed Pharmaceuticals Amends Preferred Investment Options Exhibit 99.1 NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Amends Preferred Investment Options Vancouver, BC – April 27, 2026 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molec
April 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2026 INMED PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2026 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
April 3, 2026	424B5	InMed Pharmaceuticals Inc. Up to $1,213,648 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-294503 PROSPECTUS SUPPLEMENT (to Prospectus dated March 30, 2026) InMed Pharmaceuticals Inc. Up to $1,213,648 Common Shares We have entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated April 7, 2022, as amended by that certain amendment dated June 27, 2024, relating to t
April 3, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2026 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2026 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
March 30, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2026 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39685 98-1428279 (State or other jurisdiction (Commission (IRS Em
March 30, 2026	EX-99.1	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance VANCOUVER, British Columbia - March 27, 2026 - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disea
March 26, 2026	CORRESP	March 26, 2026 March 26, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
March 25, 2026	LETTER	LETTER March 25, 2026 Eric Adams Chief Executive Officer InMed Pharmaceuticals Inc. Suite 1445 885 West Georgia St. Vancouver, British Columbia Canada V6C 3E8 Re: InMed Pharmaceuticals Inc. Registration Statement on Form S-3 Filed March 20, 2026 File No. 333-294503 Dear Eric Adams: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 a
March 23, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39685 98-1428279 (State or other jurisdiction (Commission (IRS Em
March 23, 2026	EX-99.1	InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials Consist
March 20, 2026	S-3	As filed with the Securities and Exchange Commission on March 20, 2026 As filed with the Securities and Exchange Commission on March 20, 2026 Registration No.
March 20, 2026	EX-FILING FEES	CALCULATION OF FILING FEE TABLES InMed Pharmaceuticals Inc. Table 1: Newly Registered and Carry Forward Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 InMed Pharmaceuticals Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Sha
March 9, 2026	EX-99.1	InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities Targeting Initiati
March 9, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39685 98-1428279 (State or other jurisdiction (Commission (IRS Emp
March 6, 2026	EX-99.1	2 Exhibit 99.1 Pro Forma Information on Continuing Operations The following unaudited pro forma consolidated financial information of InMed Pharmaceuticals Inc. (the “Company”) is derived from its historical consolidated financial statements and should be read in conjunction with the audited financial statements and notes thereto appearing in its Annual Report on Form 10-K for the year ended June 30
March 6, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2026 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2026 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
March 6, 2026	EX-99.2	InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline Exhibit 99.2 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline Vancouver, British Columbia – March 6, 2026. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company fo
February 12, 2026	EX-99.1	InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email : [email protected] www.inmedpharma.com InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update Vancouver, British Columbia - February 11, 2026 - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on
February 12, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Febru UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2026 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39685 98-1428279 (State or other jurisdiction (Commission (IRS
February 11, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTI
December 18, 2025	EX-99.1	InMed Announces Results of 2025 Annual General and Special Meeting NASDAQ: INM 1445 - 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Results of 2025 Annual General and Special Meeting Vancouver, British Columbia - December 17, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary sma
December 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Decem UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2025 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 001-39685 98-1428279 (State or other jurisdiction (Commission (IRS
December 15, 2025	EX-99.1	InMed Provides Update on BayMedica Commercial Business Exhibit 99.1 NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Provides Update on BayMedica Commercial Business Vancouver, British Columbia – December 12, 2025 – InMed Pharmaceuticals Inc. (Nasdaq: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprieta
December 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025 INMED PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
December 8, 2025	S-8	As filed with the Securities and Exchange Commission on December 8, 2025 As filed with the Securities and Exchange Commission on December 8, 2025 Registration No.
December 8, 2025	EX-FILING FEES	CALCULATION OF FILING FEE TABLES InMed Pharmaceuticals Inc. Table 1: Newly Registered Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 InMed Pharmaceuticals Inc. Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common shares, no par value (1) Other 300,000 $ 1.31 $ 393,000.00 0.0001381 $ 54.28 Tot
November 19, 2025	EX-99.1	InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for its Alzheimer’s Disease Candidate INM-901 Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for its Alzheimer’s Disease Candidate INM-901 ● Data demonstrate a favorable bioavailability profile of INM-901 oral formulation ● Data will support design and p
November 19, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 INMED PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUT
November 3, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
November 3, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
October 24, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
October 24, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 ☐ TRANSITION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39685
October 16, 2025	EX-99.1	InMed Pharmaceuticals Appoints Mr. John Bathery to Board of Directors Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Appoints Mr. John Bathery to Board of Directors Vancouver, British Columbia – October 16, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of
October 16, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2025 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2025 INMED PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commis
October 14, 2025	EX-99.1	Filed via SEDAR+ Exhibit 99.1 October 10, 2025 Filed via SEDAR+ To All Applicable Exchanges and Securities Administrators Subject: InMed Pharmaceuticals Inc. (the “Issuer”) Notice of Meeting and Record Date Dear Sir/Madam: We are pleased to confirm the following information with respect to the Issuer’s upcoming meeting of securityholders: Meeting Type: Annual General and Special Meeting Meeting Date: December 17,
October 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2025 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 14, 2025	EX-99.1	InMed Pharmaceuticals Appoints Mr. Neil Klompas to it’s Board of Directors Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Appoints Mr. Neil Klompas to it’s Board of Directors Vancouver, British Columbia – October 9, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline
September 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2025 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 23, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39685 INMED PHARMACEUTIC
September 23, 2025	EX-19.1	INMED PHARMACEUTICALS INC. (“InMed” or the “Company”) INSIDER TRADING POLICY Exhibit 19.1 INMED PHARMACEUTICALS INC. (“InMed” or the “Company”) INSIDER TRADING POLICY During the course of your relationship as a director, officer or employee of the Company, its subsidiaries and their affiliates, you may receive material information that is not yet publicly available about the Company or about publicly-traded companies with which the Company has business dealings. Because of
September 23, 2025	EX-99.1	Filed via SEDAR+ Exhibit 99.1 September 23, 2025 Filed via SEDAR+ To All Applicable Exchanges and Securities Administrators Subject: InMed Pharmaceuticals Inc. (the “Issuer”) Notice of Meeting and Record Date Dear Sir/Madam: We are pleased to confirm the following information with respect to the Issuer’s upcoming meeting of securityholders: Meeting Type: Annual General Meeting Meeting Date: December 17, 2025 Recor
September 23, 2025	EX-99.1	InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update ● Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer’s disease pathology ● Further develops INM-089 demons
September 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2025 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 8, 2025	EX-99.1	InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Vancouver, British Columbia – September 05, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developi
September 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2025 INMED PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
August 5, 2025	424B3	InMed Pharmaceuticals Inc. 3,904,726 Common Shares Filed pursuant to Rule 424(b)(3) Registration Number 333-288594 PROSPECTUS InMed Pharmaceuticals Inc.
August 1, 2025	S-1/A	As filed with the Securities and Exchange Commission on July 31, 2025 As filed with the Securities and Exchange Commission on July 31, 2025 Registration No.
July 31, 2025	CORRESP	INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 VIA EDGAR July 31, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: InMed Pharmaceuticals Inc. – Withdrawal of Acceleration Request for Registration Statement on Form S-1 Originally Filed on July 9, 2025 and Accele
July 28, 2025	EX-99.1	InMed to Present INM-901 Data at Alzheimer’s Association International Conference (AAIC) 2025 Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Present INM-901 Data at Alzheimer’s Association International Conference (AAIC) 2025 ● Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity Vancouver, British Columbia – July 28, 202
July 28, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
July 14, 2025	LETTER	LETTER July 14, 2025 Eric Adams Chief Executive Officer InMed Pharmaceuticals Inc. Suite 1445 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 Re: InMed Pharmaceuticals Inc. Registration Statement on Form S-1 Filed July 9, 2025 File No. 333-288594 Dear Eric Adams: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and
July 14, 2025	CORRESP	INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 VIA EDGAR July 14, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: InMed Pharmaceuticals Inc. Acceleration Request for Registration Statement on Form S-1 Filed July 9, 2025 File No. 333-288594 Ladies and Gentlemen
July 9, 2025	S-1	As filed with the Securities and Exchange Commission on July 9, 2025 As filed with the Securities and Exchange Commission on July 9, 2025 Registration No.
July 9, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) InMed Pharmaceuticals Inc.
June 30, 2025	EX-4.1	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2025). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 30, 2025	EX-4.2	Form of Preferred Investment Option (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2025). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 30, 2025	EX-10.2	Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 24, 2025, between InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This
June 30, 2025	EX-99.1	InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules Vancouver, British Columbia – June 25, 2025 – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused
June 30, 2025	EX-10.1	Form of Securities Purchase Agreement dated June 24, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2025). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 24, 2025, between InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purc
June 30, 2025	EX-4.3	Form of Placement Agent Preferred Investment Option (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2025). Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 30, 2025	EX-99.2	InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules Exhibit 99.2 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules Vancouver, British Columbia – June 26, 2025 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical comp
June 30, 2025	EX-10.3	Form of Existing Investment Option Amendment (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2025). Exhibit 10.3 June 24, 2025 Holder of Warrants to Purchase Common Shares issued on October 23, 2023 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on or about the date hereof (the “Offering”) by InMed Pharmaceuticals Inc. (the “Company”) of its common shares, without par value (“Common Shares”), pre-funded warrants to purchase Common Shares and preferred in
June 30, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (C
June 24, 2025	EX-99.1	InMed’s INM-901 Significantly Reduces Neuroinflammation in Alzheimer’s Disease Ex Vivo Study Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed’s INM-901 Significantly Reduces Neuroinflammation in Alzheimer’s Disease Ex Vivo Study ● Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/Gro ● Significantly reduces levels of
June 24, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
June 13, 2025	EX-10.1	Amendment to Standby Equity Purchase Agreement, dated June 13, 2025, by and between the Company and YA II PN, LTD (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 13, 2025). Exhibit 10.1 AMENDMENT TO STANDBY EQUITY PURCHASE AGREEMENT THIS AMENDMENT (the “Amendment”), dated as of June 13, 2025, to the Standby Equity Purchase Agreement (the “SEPA”), dated as of December 13, 2024, by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”) and INMED PHARMACEUTICALS INC., a company organized under the laws of the Province of British Columbi
June 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
June 13, 2025	EX-16.1	Letter from Marcum LLP, dated June 12, 2025, addressed to the Securities and Exchange Commission. Exhibit 16.1 June 12, 2025 Mr. Eric A. Adams InMed Pharmaceuticals Inc. 1445, 885 West Georgia St. Vancouver, B.C. Canada V6C 3E8 Re: InMed Pharmaceuticals Inc. Dear Mr. Adams: This is to confirm that the client-auditor relationship between InMed Pharmaceuticals Inc. (Commission File Number 0001728328) and Marcum llp has ceased effective June 12, 2025. Very truly yours, /s/ Marcum LLP Marcum LLP S
May 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
May 16, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
May 13, 2025	EX-99.1	InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update Vancouver, British Columbia – May 12, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a
May 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 INMED PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissio
May 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTICAL
April 29, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 25, 2025	EX-99.1	*REVISED* Filed via SEDAR+ Exhibit 99.1 April 25, 2025 *REVISED* Filed via SEDAR+ To All Applicable Exchanges and Securities Administrators Subject: InMed Pharmaceuticals Inc. (the “Issuer”) Notice of Meeting and Record Date Dear Sir/Madam: We are pleased to confirm the following information with respect to the Issuer’s upcoming meeting of securityholders: Meeting Type: Special Meeting Meeting Date: June 13, 2025 Record
April 25, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
April 8, 2025	EX-99.1	Filed via SEDAR+ Exhibit 99.1 April 4, 2025 Filed via SEDAR+ To All Applicable Exchanges and Securities Administrators Subject: InMed Pharmaceuticals Inc. (the “Issuer”) Notice of Meeting and Record Date Dear Sir/Madam: We are pleased to confirm the following information with respect to the Issuer’s upcoming meeting of securityholders: Meeting Type: Special Meeting Meeting Date: June 13, 2025 Record Date for Notic
April 8, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
February 14, 2025	EX-99.1	RESIGNATION Exhibit 99.1 RESIGNATION TO: lnMed Pharmaceuticals Inc. (the “Company”) Attention: Andrew Hull, Chairman Dear Andrew, I hereby tender my resignation for approval by the Company’s board of directors. Further, I hereby resign as a member of the Company’s Compensation Committee and Governance and Nomination Committee, effective immediately. DATED: December 18, 2024 /s/ Janet Grove JANET GROVE
February 14, 2025	EX-99.2	InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Exhibit 99.2 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Vancouver, British Columbia – February 12, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on develo
February 14, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation
February 13, 2025	EX-99.1	InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update Vancouver, British Columbia – February 12, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company“), a pharmaceutical company focused on develo
February 13, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
February 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTI
February 3, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
February 3, 2025	EX-99.1	InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration ● INM-089 IVT formulation selected for continued development ● Demonstrated successful delivery at doses up to 10 times the projected therapeu
January 22, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
January 22, 2025	EX-99.1	InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds ● Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds ● Patent covers novel analog compounds for therapeutic applic
January 21, 2025	EX-99.1	InMed’s INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer’s Disease Study Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed’s INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer’s Disease Study ● INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer’s ● Statistically signif
January 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
January 2, 2025	424B3	3,000,000 Common Shares PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration Number 333-284029 3,000,000 Common Shares This prospectus relates to the offer and resale by the selling shareholder identified herein, or the Selling Shareholder, or any of its pledgees, donees, assignees and successors-in-interest, or collectively, the permitted transferees, of up to 3,000,000 of our common shares, no par value per share, or the common shares.
December 30, 2024	CORRESP	INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 INMED PHARMACEUTICALS INC. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 VIA EDGAR December 30, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: InMed Pharmaceuticals Inc. Acceleration Request for Registration Statement on Form S-1 Filed December 23, 2024 (as amended by Pre-Effective Am
December 30, 2024	S-1/A	As filed with the Securities and Exchange Commission on December 30, 2024 As filed with the Securities and Exchange Commission on December 30, 2024 Registration No.
December 27, 2024	LETTER	LETTER December 27, 2024 Eric A. Adams President and Chief Executive Officer InMed Pharmaceuticals Inc. Suite 1445 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 Re: InMed Pharmaceuticals Inc. Registration Statement on Form S-1 Filed December 23, 2024 File No. 333-284029 Dear Eric A. Adams: This is to advise you that we have not reviewed and will not review your registration statement.
December 23, 2024	S-1	As filed with the Securities and Exchange Commission on December 23, 2024 As filed with the Securities and Exchange Commission on December 23, 2024 Registration No.
December 23, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) InMed Pharmaceuticals Inc.
December 20, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common shares, no
December 20, 2024	S-8	As filed with the Securities and Exchange Commission on December 19, 2024 As filed with the Securities and Exchange Commission on December 19, 2024 Registration No.
December 19, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation
December 19, 2024	EX-99.1	InMed Announces Results of 2024 Annual General Meeting EX-99.1 2 ea022531101ex99-1inmed.htm PRESS RELEASE, DATED DECEMBER 18, 2024 Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Results of 2024 Annual General Meeting Vancouver, British Columbia – December 18, 2024. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”),
December 18, 2024	EX-10.1	Standby Equity Purchase Agreement, dated December 13, 2024, by and between the Company and YA II PN, LTD (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 18, 2024). Exhibit 10.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of December 13, 2024, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and INMED PHARMACEUTICALS INC., a company organized under the laws of British Columbia, Can
December 18, 2024	EX-99.1	InMed Enters Into Standby Equity Purchase Agreement Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Enters Into Standby Equity Purchase Agreement Vancouver, British Columbia – December 17, 2024. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small
December 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 INMED PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 20, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 20, 2024	EX-99.1	InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System ● Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effects ● Supports therapeutic potential of cannabinol fo
November 15, 2024	EX-99.1	InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update Vancouver, British Columbia – November 14, 2024. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on develop
November 15, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 14, 2024	SC 13G/A	INM / InMed Pharmaceuticals Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUT
November 12, 2024	SC 13G	INM / InMed Pharmaceuticals Inc. / AdvisorShares Trust Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) InMed Pharmaceuticals, Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 457637601 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to designate the rule pursu
November 12, 2024	EX-99.1	InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules Exhibit 99.1 NASDAQ: INM Suite 1445-885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules Vancouver, BC – November 8, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focused on developing a pipeline of proprietary
November 12, 2024	8-K	Regulation FD Disclosure, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
November 5, 2024	EX-99.1	InMed Pharmaceuticals Announces Decision by Nasdaq Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy Nasdaq Listing Rules Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces Decision by Nasdaq Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy Nasdaq Listing Rules Vancouver, British Columbia – November 5, 2024. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed”
November 5, 2024	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 28, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
October 28, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
October 28, 2024	EX-99.1	InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer’s Disease Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer’s Disease Vancouver, British Columbia–October 28, 2024 (InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or
October 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 24, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 24, 2024	EX-99.1	InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer’s Disease Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer’s Disease Vancouver, BC – October 24, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focused on developing a pipe
October 23, 2024	EX-99.1	InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board Vancouver, BC – October 22, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focus
October 23, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 17, 2024	424B3	InMed Pharmaceuticals Inc. Up to $875,546 Common Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-262532 PROSPECTUS SUPPLEMENT (To Prospectus dated February 4, 2022, as supplemented) InMed Pharmaceuticals Inc. Up to $875,546 Common Shares We have entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated April 7, 2022, as amended by that certain amendment dated June 27, 20
September 30, 2024	EX-21.1	Subsidiaries of the Company (incorporated by reference to Exhibit 21.1 of the Company’s Annual Report on Form 10-K filed with the SEC on September 30, 2024). Exhibit 21.1 SUBSIDIARIES OF INMED PHARMACEUTICALS INC. Subsidiary Jurisdiction Biogen Sciences Inc. BC Sweetnam Consulting Inc. BC InMed Pharmaceuticals Ltd. Delaware BayMedica, LLC Delaware
September 30, 2024	EX-97.1	Compensation Clawback Policy Exhibit 97.1 InMed Pharmaceuticals Inc. EXECUTIVE COMPENSATION CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of InMed Pharmaceuticals Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation ph
September 30, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39685 INMED PHARMACEUTIC
September 30, 2024	EX-99.1	InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update ● Advances INM-901 program targeting several biological pathways associated with Alzheimer’s disease ● Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration ● $4.6M revenues in fiscal year 2024, representing a 11% incr
September 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 30, 2024	EX-10.20	Scientific Advisory Board Consulting Agreement, dated as of September 4, 2024, between the Company and Barry Greenberg, Ph.D. (incorporated by reference to Exhibit 10.20 to the Company’s Annual Report on Form 10-K filed with the SEC on September 30, 2024). Exhibit 10.20 SCIENTIFIC ADVISORY BOARD CONSULTING AGREEMENT THIS AGREEMENT (this “Agreement”) dated for reference the 4th day of September 2024, (the “Effective Date”) BETWEEN: INMED PHARMACEUTICALS INC., a company incorporated under the laws of British Columbia having an office at Suite 1445, 885 W. Georgia Street, Vancouver, British Columbia, Canada V6C 3E8 (“InMed”) AND: Barry Greenberg, PhD,
September 30, 2024	EX-10.19	Consulting Agreement, dated as of May 17, 2024, between the Company and Alexandra D. J. Mancini, d.b.a True North Synergy Inc. (incorporated by reference to Exhibit 10.19 to the Company’s Annual Report on Form 10-K filed with the SEC on September 30, 2024). Exhibit 10.19 CONSULTING AGREEMENT THIS AGREEMENT made as of the 17th day of May, 2024 with an effective date of 1st day of July, 2024 (the “Effective Date”). BETWEEN: InMed Pharmaceuticals Inc., a corporation registered in the Province of British Columbia and having its principal place of business at 310-815 W. Hastings St., Vancouver, BC, V6C 1B4, (the “Company”) AND: ALEXANDRA D. J. MANCINI, d.
September 30, 2024	EX-4.13	Description of Securities of InMed Pharmaceuticals Inc. Exhibit 4.13 Description of Registrant’s Securities Registered under Section 12 of the Securities Exchange Act of 1934 The following description (this “Description”) of our Common Shares is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Articles (our “Articles”), which has been filed with the Securities and E
September 26, 2024	EX-99.1	Filed via SEDAR+ Exhibit 99.1 September 26, 2024 Filed via SEDAR+ To All Applicable Exchanges and Securities Administrators Subject: InMed Pharmaceuticals Inc. (the “Issuer”) Notice of Meeting and Record Date Dear Sir/Madam: We are pleased to confirm the following information with respect to the Issuer’s upcoming meeting of securityholders: Meeting Type: Annual General Meeting Meeting Date: December 18, 2024 Recor
September 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 20, 2024	EX-99.1	InMed Receives Nasdaq Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date Exhibit 99.1 NASDAQ: INM Suite 1445-885 W. Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Receives Nasdaq Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date Vancouver, BC – September 20, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical company focus
August 21, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commis
August 21, 2024	EX-99.1	InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents Exhibit 99.1 NASDAQ: INM 1445 – 885 West Georgia St. Vancouver, BC, Canada V6C 3E8 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents ● InMed’s intellectual property portfolio totals 13 patent families covering new chemical entities, formulations, manufacturing methods and methods of use Vancou
August 20, 2024	EX-99.1	InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer’s Disease Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer’s Disease ● High bioavailability of INM-901 oral formulation provides similar drug concentration levels in the brain as intraperitoneal (IP) injection Vancouver
August 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 INMED PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commis
July 30, 2024	EX-99.1	InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer’s Disease Study, Confirming Previous Short-Term Pilot Study Data Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer’s Disease Study, Confirming Previous Short-Term Pilot Study Data ● Results confirm improvements in cognitive function, memory and locomo
July 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
June 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (C
June 28, 2024	EX-10.1	Amendment No. 1, dated June 27, 2024, to the At the Market Offering Agreement dated April 7, 2022 by and between InMed Pharmaceuticals Inc., and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 28, 2024). Exhibit 10.1 June 27, 2024 InMed Pharmaceuticals Inc. Suite 310 – 815 W. Hastings Street Vancouver, British Columbia V6C 1B4 Attention: Eric A. Adams, President and Chief Executive Officer Dear Mr. Adams: Reference is made to the At The Market Offering Agreement, dated as of April 7, 2022 (the “ATM Agreement”), between InMed Pharmaceuticals Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wai
June 28, 2024	424B3	InMed Pharmaceuticals Inc. Up to $1,030,190 Common Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-262532 PROSPECTUS SUPPLEMENT (To Prospectus dated February 4, 2022, as supplemented) InMed Pharmaceuticals Inc. Up to $1,030,190 Common Shares We have entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated April 7, 2022, as amended by that certain amendment dated June 27,
June 11, 2024	EX-99.1	InMed to Present at the Emerging Growth Conference Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Present at the Emerging Growth Conference Vancouver, BC – June 10, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small
June 11, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
May 14, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissio
May 14, 2024	EX-99.1	InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update ● Reported positive preclinical data in both its Alzheimer’s and dry AMD programs ● Closed Fiscal Q3 with cash position of US$7.9 million Vanco
May 14, 2024	EX-10.1	Scientific Advisory Board Consulting Agreement, dated as of April 12, 2024, between InMed Pharmaceuticals Inc. and David G. Morgan. Exhibit 10.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer’s Expert, to the Company’s Scientific Advisory Board Vancouver, BC – April 18, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, deve
May 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTICAL
April 18, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
April 18, 2024	EX-99.1	InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer’s Expert, to the Company’s Scientific Advisory Board Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer’s Expert, to the Company’s Scientific Advisory Board Vancouver, BC – April 18, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, deve
April 16, 2024	EX-99.1	InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration ● Small molecule drug acting as a preferential signaling ligand for CB1/CB2 ● Delivers improved retinal pigment epithelium integrity, neuroprotection and ph
April 16, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
April 5, 2024	EX-99.1	InMed’s INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer’s Disease Studies Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed’s INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer’s Disease Studies ● INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling
April 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
March 20, 2024	EX-99.1	InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance Vancouver, BC – March 20, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing, development and commercialization of rar
March 20, 2024	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commiss
February 14, 2024	SC 13G/A	INMED PHARMACEUTICALS INC / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-inm123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* INMED PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 457637601 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appro
February 14, 2024	EX-99.1	InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update ● Advancing two new preclinical programs in Alzheimer’s and Age-Related Macular Degeneration ● Closed calendar year 2023 with cash position of US$9.5 million
February 14, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
February 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUTI
February 9, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
February 9, 2024	EX-10.1	Employment Agreement by and between the Company and Narinder Netta “Neeta” Jagpal, effective February 20, 2024 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT made this 20th day of February, 2024 (the “Effective Date”) BETWEEN: INMED PHARMACEUTICALS INC., a company incorporated under the laws of British Columbia with offices at Suite 310, 815 West Hastings St., Vancouver, B.C., V6C 1B4 (the “Company”) AND: Narinder Netta “Neeta” Jagpal (the “Executive”), of 14280 90A Ave., Surrey, BC V3V 7X9 (ea
February 9, 2024	EX-99.1	InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer Vancouver, BC – February 9, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the ma
January 19, 2024	EX-99.1	InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET Vancouver, BC – January 18, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:
January 19, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
January 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
January 16, 2024	EX-99.1	InMed Pharmaceuticals Provides Business Update and Milestones for 2024 Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Provides Business Update and Milestones for 2024 ● Advancing INM-901 as a multimodal treatment option for Alzheimer’s Disease ● Advancing INM-089 in the treatment of Age-related Macular Degeneration ● Actively seeking partne
January 4, 2024	SC 13G	INM / InMed Pharmaceuticals Inc. / SABBY MANAGEMENT, LLC - INM 13G 1.03.24 Passive Investment SC 13G 1 inm0124.txt INM 13G 1.03.24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* InMed Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 457637502 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
December 22, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common shares, no
December 22, 2023	S-8	As filed with the Securities and Exchange Commission on December 21, 2023 As filed with the Securities and Exchange Commission on December 21, 2023 Registration No.
December 21, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3968
December 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 InMed Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 InMed Pharmaceuticals Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation
December 20, 2023	EX-99.1	InMed Announces Results of 2023 Annual General Meeting Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Results of 2023 Annual General Meeting Vancouver, BC – December 19, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabi
November 29, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 29, 2023	EX-99.1	InMed Expands its Pharmaceutical Pipeline with INM-089 Targeting the Treatment of Age-Related Macular Degeneration Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Expands its Pharmaceutical Pipeline with INM-089 Targeting the Treatment of Age-Related Macular Degeneration ● INM-089 improves retinal function in in vivo preclinical AMD disease model ● Establishes cannabinol (CBN) analog candidate in a n
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39685 INMED PHARMACEUT
November 14, 2023	EX-4.13	Description of Securities of InMed Pharmaceuticals Inc. Exhibit 4.13 Description of Registrant’s Securities Registered under Section 12 of the Securities Exchange Act of 1934 The following description (this “Description”) of our common shares is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Articles (our “Articles”), which has been filed with the Securities and E
November 14, 2023	EX-99.1	InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update Vancouver, BC – November 14, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development,
November 14, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
November 13, 2023	424B3	12,569,564 Common Shares InMed Pharmaceuticals Inc. Filed pursuant to Rule 424(b)(3) Registration Number 333-275410 PROSPECTUS 12,569,564 Common Shares InMed Pharmaceuticals Inc.
November 10, 2023	LETTER	LETTER United States securities and exchange commission logo November 9, 2023 Eric A. Adams President and Chief Executive Officer InMed Pharmaceuticals Inc. Suite 310 815 West Hastings Street Vancouver, British Columbia V6C 1B4 Canada Re: InMed Pharmaceuticals Inc. Registration Statement on Form S-1 Filed November 8, 2023 File No. 333-275410 Dear Eric A. Adams: This is to advise you that we have not revi
November 9, 2023	CORRESP	INMED PHARMACEUTICALS INC. Suite 310 - 815 West Hastings Street Vancouver, British Columbia, Canada V6C 1B4 INMED PHARMACEUTICALS INC. Suite 310 - 815 West Hastings Street Vancouver, British Columbia, Canada V6C 1B4 VIA EDGAR November 9, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: InMed Pharmaceuticals Inc. Acceleration Request for Registration Statement on Form S-1 Filed November 8, 2023 File No. 333-275410 Ladies and
November 8, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) InMed Pharmaceuticals Inc.
November 8, 2023	S-1	As filed with the Securities and Exchange Commission on November 8, 2023 As filed with the Securities and Exchange Commission on November 8, 2023 Registration No.
November 2, 2023	EX-99.1	InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 Vancouver, BC – November 2, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutica
November 2, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
October 30, 2023	EX-4.2	Form of Preferred Investment Option (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 30, 2023	EX-10.3	Form of Inducement Letter dated October 24, 2023 (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 10.3 INMED PHARMACEUTICALS INC. October 24, 2023 Holder of Preferred Investment Options Issued in November 2022 Re: Inducement Offer to Exercise Preferred Investment Options Issued in November 2022 Dear Holder: InMed Pharmaceuticals Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (i) new preferred investment options to pur
October 30, 2023	EX-4.1	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 30, 2023	EX-10.1	Form of Securities Purchase Agreement dated October 24, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 24, 2023, between InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “P
October 30, 2023	EX-99.1	InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules Vancouver, BC – October 24, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM)
October 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 INMED PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation)
October 30, 2023	EX-4.3	Form of Placement Agent Preferred Investment Option (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 30, 2023	EX-99.2	InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules Exhibit 99.2 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules Vancouver, BC – October 26, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”
October 30, 2023	EX-10.2	Registration Rights Agreement, dated November 17, 2022, between InMed Pharmaceuticals Inc. and the purchasers thereto (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on October 30, 2023). Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 24, 2023, between InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). T
October 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
October 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
October 24, 2023	EX-99.1	InMed Pharmaceuticals Inc.’s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer’s Disease in Preclinical Proof-of-Concept Studies Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Inc.’s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer’s Disease in Preclinical Proof-of-Concept Studies ● In vitro Alzheimer’s disease studies show that INM-901 treated groups display neuroprotection and ex
October 24, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commi
September 29, 2023	EX-99.1	InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update ● Completed Phase 2 Clinical Trial demonstrating anti-itch activity of INM-755 (CBN) topical cream ● $4.1M revenues in fiscal year 2023, representi
September 29, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 29, 2023	EX-4.13	Description of Securities of InMed Pharmaceuticals Inc. Exhibit 4.13 Description of Registrant’s Securities Registered under Section 12 of the Securities Exchange Act of 1934 The following description (this “Description”) of our common shares is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Articles (our “Articles”), which has been filed with the Securities and E
September 29, 2023	NT 10-K	SEC FILE NUMBER UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 001-39685 NOTIFICATION OF LATE FILING CUSIP NUMBER 457637601 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023
September 29, 2023	EX-21.1	Subsidiaries of the Company. Exhibit 21.1 SUBSIDIARIES OF INMED PHARMACEUTICALS INC. Subsidiary Jurisdiction Biogen Sciences Inc. BC Sweetnam Consulting Inc. BC InMed Pharmaceuticals Ltd. Delaware BayMedica, LLC Delaware
September 29, 2023	EX-10.13	Consulting Agreement dated as of April 1, 2022, between InMed Pharmaceuticals Inc. and Brenda Edwards. Exhibit 10.13 CONSULTING AGREEMENT THIS AGREEMENT made as of the 1st day of April, 2022. BETWEEN: InMed Pharmaceuticals Inc., a corporation registered in the Province of British Columbia and having its principal place of business at 310-815 W. Hastings St., Vancouver, BC, V6C 1B4, (the “Company”) AND: Brenda Edwards, an individual having a residential address at 111-1232 Johnson Street, Coquitlam,
September 29, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39685 INMED PHARMACEUTIC
September 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 25, 2023	EX-99.1	Filed via SEDAR Exhibit 99.1 September 25, 2023 Filed via SEDAR To All Applicable Exchanges and Securities Administrators Subject: InMed Pharmaceutical Inc. (the "Issuer") Notice of Meeting and Record Date Dear Sir/Madam: We are pleased to confirm the following information with respect to the Issuer's upcoming meeting of securityholders: Meeting Type: Annual General Meeting Meeting Date: December 19, 2023 Record
September 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 INMED PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Com
September 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 INMED PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Comm
September 8, 2023	EX-99.1	InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference Vancouver, BC – September 7, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development, manufactur
July 24, 2023	EX-99.1	InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET Vancouver, BC – July 21, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development,
July 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 INMED PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
July 20, 2023	EX-99.1	InMed Provides Update on BayMedica Rare Cannabinoid Business Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Provides Update on BayMedica Rare Cannabinoid Business ● $2.3M revenues (unaudited) in Q4 2023, representing 123% increase quarter over quarter (“QoQ”) ● Optimized and scaled up manufacturing processes over the last 12 months to meet increa
June 22, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissi
June 22, 2023	EX-99.1	InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa Exhibit 99.1 NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: [email protected] www.inmedpharma.com InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa ● An exploratory clinical evaluation of the Phase 2 clinical trial data showed a positive indication of enhanced anti-itch activity for INM-755 ca
June 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 INMED PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 INMED PHARMACEUTICALS INC. (Exact Name of Company as Specified in Charter) British Columbia 001-39685 98-1428279 (State or Other Jurisdiction of Incorporation) (Commissio

INM / InMed Pharmaceuticals Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings